Acadia Pharma (ACAD) Tops Q3 EPS by 5c, Beats on Revenue, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $20.19 -1.22%
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.40), $0.05 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $211.7 million versus the consensus estimate of $192.2 million.
For FY23 the company guides:
- NUPLAZID net sales in the range of $537.5 to $545 million.
- R&D expense in the range of $340 to $350 million.
- SG&A expense in the range of $390 to $400 million
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Hexcel falls on revenue miss and weak guidance
- Liberty Oilfield Services (LBRT) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
